HDAC6 inhibition reduces cardiac fibrosis, enhances mitochondrial function and demonstrates comparable efficacy as empagliflozin in a mouse model of heart failure with preserved ejection fraction
Tenaya Therapeutics, South San Francisco (United States of America)
0
follower
32
more
presentations
in this session
Comparison 8 vs. 10mm fenestration size of the atrial flow regulator in patients with heart failure with reduced and preserved ejection fraction: an analysis of the Prelieve Trial
The impact of intravenous ferric carboxymaltose on echocardiographic markers of cardiac function in patients with HFrEF and cardiac implantable electronic devices: sub-analysis of the RESAFE-HF trial